K
Kenneth B. Ain
Researcher at University of Kentucky
Publications - Â 55
Citations - Â 5595
Kenneth B. Ain is an academic researcher from University of Kentucky. The author has contributed to research in topics: Thyroid cancer & Thyroid carcinoma. The author has an hindex of 29, co-authored 55 publications receiving 5104 citations. Previous affiliations of Kenneth B. Ain include Veterans Health Administration & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
Robert C. Smallridge,Kenneth B. Ain,Kenneth B. Ain,Sylvia L. Asa,Sylvia L. Asa,Keith C. Bible,James D. Brierley,James D. Brierley,Kenneth D. Burman,Electron Kebebew,Nancy Y. Lee,Yuri E. Nikiforov,M. Sara Rosenthal,Manisha H. Shah,Ashok R. Shaha,R. Michael Tuttle +15 more
TL;DR: These are the first comprehensive guidelines for ATC and provide recommendations for management of this extremely aggressive malignancy.
Journal ArticleDOI
Outcomes of patients with differentiated thyroid carcinoma following initial therapy.
Jacqueline Jonklaas,Nicholas J. Sarlis,Nicholas J. Sarlis,Danielle R. Litofsky,Kenneth B. Ain,S. Thomas Bigos,James D. Brierley,David S. Cooper,Bryan R. Haugen,Paul W. Ladenson,James Magner,Jacob Robbins,Douglas S. Ross,Monica C. Skarulis,Harry R. Maxon,Steven I. Sherman +15 more
TL;DR: It is confirmed that near-total thyroidectomy is indicated in high-risk patients and radioactive iodine therapy is beneficial for stage II, III, and IV patients, and it is shown for the first time that superior outcomes are associated with aggressive thyroid hormone suppression therapy in high risk patients, but are achieved with modest suppression in stage II patients.
Journal ArticleDOI
American thyroid association guidelines for detection of thyroid dysfunction
Paul W. Ladenson,Peter Singer,Kenneth B. Ain,N. Bagchi,S. Thomas Bigos,Elliot G. Levy,Steven A. Smith,Gilbert H. Daniels +7 more
TL;DR: The American Thyroid Association recommends that adults be screened for thyroid dysfunction by measurement of the serum thyrotropin concentration, beginning at age 35 years and every 5 years thereafter.
Journal Article
High Prevalence of BRAF Gene Mutation in Papillary Thyroid Carcinomas and Thyroid Tumor Cell Lines
TL;DR: Observations suggest that mutated BRAF gene may cooperate with RET/PTC to induce the oncogenesis of PTC, and a large number of BRAF-mutated PTCs also expressed RET, indicating that the RET proto-oncogene is rearranged in these BRA fusions.
Journal ArticleDOI
Thyrotropin Suppression and Disease Progression in Patients with Differentiated Thyroid Cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry
David S. Cooper,Bonny Specker,Mona Ho,Matthew Sperling,Paul W. Ladenson,Douglas S. Ross,Kenneth B. Ain,S. Thomas Bigos,James Brierley,Bryan R. Haugen,Irwin Klein,Irwin Klein,Jacob Robbins,Steven I. Sherman,Terry A. Taylor,Harry R. Maxon +15 more
TL;DR: The relation of TSH suppression to baseline disease characteristics and to the likelihood of disease progression in a cohort of thyroid cancer patients who have been followed in a multicenter thyroid cancer registry is examined.